Louise M. Downey

Kingston Upon Hull, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Modified Delphi expert consensus on the optimal intravitreal treatment pathway for centre involving diabetic macular oedema patients within the National Health Service.

Modified Delphi expert consensus on the optimal intravitreal treatment pathway for centre involving diabetic macular oedema patients within the National Health Service.

Journal: BMJ open ophthalmology

Published: February 08, 2026

Faricimab in Treatment-Naïve nAMD: Regional UK Real-World Experience.

Faricimab in Treatment-Naïve nAMD: Regional UK Real-World Experience.

Journal: Advances in therapy

Published: November 03, 2025

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel.

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel.

Journal: Eye (London, England)

Published: May 15, 2025

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Journal: Eye (London, England)

Published: May 13, 2025

Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study.

Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study.

Journal: Eye (London, England)

Published: April 07, 2025

Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept.

Expert Panel Consensus for Optimizing Outcomes in Neovascular Age-Related Macular Degeneration in the Context of Suboptimal Response to a Biosimilar: The Role of Aflibercept.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: June 10, 2024

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis.

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis.

Journal: Current medical research and opinion

Published: May 30, 2024

Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists.

Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists.

Journal: Eye (London, England)

Published: March 12, 2024

Treatment of age-related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4-year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial).

Treatment of age-related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4-year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial).

Journal: Acta ophthalmologica

Published: February 19, 2023

Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.

Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.

Journal: Health technology assessment (Winchester, England)

Published: December 21, 2022

Correction to: Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis.

Correction to: Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis.

Journal: Advances in therapy

Published: November 30, 2022

The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration.

The MATE trial: a multicentre, mixed-methodology, pilot, randomised controlled trial in neovascular age-related macular degeneration.

Journal: Pilot and feasibility studies

Published: July 15, 2022

Showing 1-12 of 54

Last Updated: 09/26/2026